On 11 June 2024, Regeneron announced that the FDA approved its Kevzara® (sarilumab) for active polyarticular juvenile idiopathic arthritis (PJIA). Kevzara® is jointly developed by Regeneron and Sanofi under a global collaboration agreement.
Kevzara® is approved in 25 countries for moderately to severely active rheumatoid arthritis after a DMARD has been used and in the US for polymyalgia rheumatica in patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.